YaoGeJu

Company directoryChina company filings

Zhejiang Yong Tai Pharma Co., Ltd. romanized

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference cad5a54937

Complete CDE snapshot
2026/11/13 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.

Drug filings

14 acceptance records as first applicant, grouped into 7 source drug names. Source data as of 2026/11/13 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Tadalafil Tablets 2 records · Latest accepted 2025/06/04

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2501964Generic2025/06/04Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
CYHS2501963Generic2025/06/04Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
Vonoprazan Fumarate Tablets 4 records · Latest accepted 2025/04/16

Supplement · 2Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2500764Supplement2025/04/16Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
CYHB2500763Supplement2025/04/16Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
CYHS2300466Generic2023/02/11Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
CYHS2300465Generic2023/02/11Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
西格列汀二甲双胍片(I) · No verified English name 1 records · Latest accepted 2023/10/12

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2302712Generic2023/10/12Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
Sitagliptin Phosphate and Metformin Hydrochloride Tablets (II) 1 records · Latest accepted 2023/10/12

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2302714Generic2023/10/12Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
Sitagliptin Phosphate Tablets 3 records · Latest accepted 2022/09/03

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2201451Generic2022/09/03Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
CYHS2201450Generic2022/09/03Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
CYHS2201449Generic2022/09/03Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
Esomeprazole Magnesium Enteric-Coated Capsules 2 records · Latest accepted 2022/06/24

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200943Generic2022/06/24Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
CYHS2200941Generic2022/06/24Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
Moxifloxacin Hydrochloride Tablets 1 records · Latest accepted 2022/01/17

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200068Generic2022/01/17Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Tadalafil Tablets CYHS2501964Generic2025/06/04Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗
Tadalafil Tablets CYHS2501963Generic2025/06/04Zhejiang Yong Tai Pharma Co., Ltd. romanizedCDE ↗

Catalogue holder records

18 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Vonoprazan Fumarate TabletsZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202534822025/03/04Generic approved under the new chemical-drug registration classificationCDE ↗
Vonoprazan Fumarate TabletsZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202534812025/03/04Generic approved under the new chemical-drug registration classificationCDE ↗
西格列汀二甲双胍片(I) · No verified English nameZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202531982025/01/14Generic approved under the new chemical-drug registration classificationCDE ↗
Sitagliptin Phosphate and Metformin Hydrochloride Tablets (II)Zhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202531992025/01/14Generic approved under the new chemical-drug registration classificationCDE ↗
Sitagliptin Phosphate TabletsZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202440512024/06/18Generic approved under the new chemical-drug registration classificationCDE ↗
Sitagliptin Phosphate TabletsZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202440492024/06/18Generic approved under the new chemical-drug registration classificationCDE ↗
Moxifloxacin Hydrochloride TabletsZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202440772024/06/18Generic approved under the new chemical-drug registration classificationCDE ↗
Sitagliptin Phosphate TabletsZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202440502024/06/18Generic approved under the new chemical-drug registration classificationCDE ↗
Esomeprazole Magnesium Enteric-Coated CapsulesZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202439202024/06/04Generic approved under the new chemical-drug registration classificationCDE ↗
Esomeprazole Magnesium Enteric-Coated CapsulesZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202439192024/06/04Generic approved under the new chemical-drug registration classificationCDE ↗
Aripiprazole TabletsZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202235622022/08/10Generic approved under the new chemical-drug registration classificationCDE ↗
Aripiprazole TabletsZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202235632022/08/10Generic approved under the new chemical-drug registration classificationCDE ↗
Duloxetine Hydrochloride Enteric CapsulesZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202233622022/06/07Generic approved under the new chemical-drug registration classificationCDE ↗
Duloxetine Hydrochloride Enteric CapsulesZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202233612022/06/07Generic approved under the new chemical-drug registration classificationCDE ↗
Duloxetine Hydrochloride Enteric CapsulesZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202233602022/06/07Generic approved under the new chemical-drug registration classificationCDE ↗
Gabapentin CapsulesZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202233202022/05/18Generic approved under the new chemical-drug registration classificationCDE ↗
Gabapentin CapsulesZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202233212022/05/18Generic approved under the new chemical-drug registration classificationCDE ↗
Gabapentin CapsulesZhejiang Yong Tai Pharma Co., Ltd. romanizedZhejiang Yong Tai Pharma Co., Ltd. romanized国药准字H202233222022/05/18Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

4 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.

NameCompany / applicantRegistration numberStatusSource update dateView source
磷酸西格列汀 · No verified English nameZhejiang Yong Tai Pharma Co., Ltd. romanizedY20210001177A2023/08/01CDE ↗
瑞舒伐他汀钙 · No verified English nameZhejiang Yong Tai Pharma Co., Ltd. romanizedY20210000962A2023/07/28CDE ↗
盐酸度洛西汀 · No verified English nameZhejiang Yong Tai Pharma Co., Ltd. romanizedY20190021263A2023/07/31CDE ↗
奈韦拉平 · No verified English nameZhejiang Yong Tai Pharma Co., Ltd. romanizedY20190006471A2026/05/11CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39
Full API register
Last successful update: 2026/11/13 06:41
NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.